Akari Therapeutics (AKTX) EBITDA (2014 - 2026)

Akari Therapeutics has disclosed EBITDA across 10 years of filings, most recently posting -$14.4 million for Q1 2026.

• EBITDA for Q1 2026 came in at -$14.4 million, down 286.12% year-over-year; the trailing twelve-month figure through Mar 2026 was -$28.0 million (down 56.3% YoY), and the FY2025 annual result was -$17.3 million, up 11.02% from the prior year.
• EBITDA came in at -$14.4 million for Q1 2026 at Akari Therapeutics, down from -$4.9 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $1.0 million in Q1 2023 to a low of -$14.4 million in Q1 2026.
• The 4-year median for EBITDA is -$4.1 million (2023), against an average of -$4.7 million.
• Across the five-year window, EBITDA slumped 627.12% in 2024 and jumped 70.47% in 2025, its largest moves.
• Akari Therapeutics' EBITDA stood at -$4.3 million in 2023, then grew by 17.59% to -$3.6 million in 2024, then sank by 37.72% to -$4.9 million in 2025, then tumbled by 192.56% to -$14.4 million in 2026.
• The last three EBITDA figures came in at -$14.4 million (Q1 2026), -$4.9 million (Q4 2025), and -$6.4 million (Q3 2025), per Business Quant data.